Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy Improves Survival in Unresectable Esophageal Cancer: a systematic review, meta-analysis, and network meta-analysis - Summary - MDSpire
Advertisement
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy Improves Survival in Unresectable Esophageal Cancer: a systematic review, meta-analysis, and network meta-analysis
To assess the advantages of integrating immunotherapy with concurrent chemoradiotherapy (CCRT) for unresectable esophageal cancer (EC).
Key Findings:
Induction immunochemotherapy plus CCRT (ICT-CCRT) significantly enhanced OS compared to CCRT alone (HR 0.52).
CCRT plus consolidation immunotherapy (CCRT-IO) also improved OS in pairwise analyses (HR 0.77).
In NMA, only ICT-CCRT showed a significant OS advantage (HR 0.75).
CCRT-IO consistently extended PFS compared to CCRT alone (HR 0.74 in pairwise, HR 0.78 in NMA).
ICT-CCRT ranked highest in NMA for both OS and PFS.
Interpretation:
ICT-CCRT significantly enhances overall survival and shows potential for improved progression-free survival, while CCRT-IO consistently improves progression-free survival.
Limitations:
Insufficient randomized controlled trials to validate efficacy.
Uncertainty regarding optimal timing and sequence of treatments.
Conclusion:
ICT-CCRT significantly enhances OS and demonstrates potential PFS benefits compared to CCRT alone, while CCRT-IO improves PFS consistently across analyses.
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 - 28.
